These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9137974)

  • 21. Positive findings on bone scan in multiple myeloma.
    Murthy NJ; Rao H; Friedman AS
    South Med J; 2000 Oct; 93(10):1028-9. PubMed ID: 11147470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
    Wittrant Y; Théoleyre S; Chipoy C; Padrines M; Blanchard F; Heymann D; Rédini F
    Biochim Biophys Acta; 2004 Sep; 1704(2):49-57. PubMed ID: 15363860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
    Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
    Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases.
    Terpos E; Efstathiou E; Christoulas D; Roussou M; Katodritou E; Dimopoulos MA
    Expert Opin Biol Ther; 2009 Apr; 9(4):465-79. PubMed ID: 19344283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Bone tissue and cancer].
    Rossi JF
    Pathol Biol (Paris); 1990 Jan; 38(1):69-79. PubMed ID: 2407992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Bone hyperresorption in multiple myeloma].
    Beaudreuil J; Orcel P
    Presse Med; 2000 Mar; 29(9):492-7. PubMed ID: 10745943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Biphosphonates in oncology].
    Khosravi Shahi P; Díaz Muñoz de la Espada V
    An Med Interna; 2005 Nov; 22(11):544-7. PubMed ID: 16454591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of clodronate in multiple myeloma.
    Delmas PD
    Bone; 1991; 12 Suppl 1():S31-4. PubMed ID: 1835398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myeloma bone disease.
    Berenson JR
    Best Pract Res Clin Haematol; 2005; 18(4):653-72. PubMed ID: 16026743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Myelomatous bone. Histomorphometric study and therapeutic effects].
    Charhon SA; Valentin-Opran A; Edouard C; Delmas PD; Meunier PJ
    Rev Rhum Mal Osteoartic; 1984 Dec; 51(11):657-62. PubMed ID: 6523017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current Controversies in the Management of Myeloma Bone Disease.
    Silbermann R; Roodman GD
    J Cell Physiol; 2016 Nov; 231(11):2374-9. PubMed ID: 26910829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathogenesis of myeloma bone disease.
    Roodman GD
    J Cell Biochem; 2010 Feb; 109(2):283-91. PubMed ID: 20014067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonsecretory multiple myeloma in two dogs.
    MacEwen EG; Patnaik AK; Hurvitz AI; Bradley R; Claypoole TF; Withrow SJ; Erlandson RA; Lieberman PH
    J Am Vet Med Assoc; 1984 May; 184(10):1283-6. PubMed ID: 6735847
    [No Abstract]   [Full Text] [Related]  

  • 34. Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.
    Mohan M; Samant RS; Yoon D; Buros AF; Branca A; Montgomery CO; Nicholas R; Suva LJ; Morello R; Thanendrarajan S; Schinke C; Yaccoby S; van Rhee F; Davies FE; Morgan GJ; Zangari M
    J Bone Miner Res; 2017 Jun; 32(6):1261-1266. PubMed ID: 28240368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rare Pedal Manifestation of Diffuse Multiple Myeloma Lesions.
    Saviet BM; Marcoux JT; Narayanasami U
    J Foot Ankle Surg; 2017; 56(2):357-361. PubMed ID: 28231967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A murine model of human myeloma bone disease.
    Garrett IR; Dallas S; Radl J; Mundy GR
    Bone; 1997 Jun; 20(6):515-20. PubMed ID: 9177864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple myeloma/hypercalcemia.
    Oyajobi BO
    Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S4. PubMed ID: 17634143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
    Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo.
    Lwin ST; Fowler JA; Drake MT; Edwards JR; Lynch CC; Edwards CM
    Mol Cancer; 2017 Feb; 16(1):49. PubMed ID: 28241871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast.
    Reagan MR; Liaw L; Rosen CJ; Ghobrial IM
    Bone; 2015 Jun; 75():161-9. PubMed ID: 25725265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.